Status:
NOT_YET_RECRUITING
Injectable Buprenorphine in Prison: a Preference Trial
Lead Sponsor:
Lifespan
Collaborating Sponsors:
National Institute on Drug Abuse (NIDA)
Conditions:
Opioid Use Disorder
Incarceration
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The goal of this pilot trial is to compare two branded extended-release buprenorphine (XR-B) formulations (Sublocade vs. Brixadi) to explore how they improve treatment retention after release from pri...
Detailed Description
This study is a pilot hybrid effectiveness-implementation trial using a partially randomized preference trial (PRPT) design to evaluate two formulations of extended-release buprenorphine (XR-B)-Subloc...
Eligibility Criteria
Inclusion
- be at least 18 years of age and incarcerated in the RIDOC facility,
- be currently diagnosed with OUD and enrolled in the RIDOC MOUD program,
- have an expected release date within 120 days of study enrollment,
- have an interest in XR-B and
- be English speaking
Exclusion
- individuals who are pregnant or planning conception,
- diagnosed with a severe or acute medical or psychiatric disability preventing safe study participation or making follow-up unlikely,
- have a release date within 21 days of initiation, or
- have previously had an allergy to buprenorphine. Post-enrollment exclusion will include individuals if there is a change in release date beyond the 120 days and therefore no longer meet original inclusion criteria. These individuals would return to usual MOUD care.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06880718
Start Date
June 1 2025
End Date
June 1 2027
Last Update
March 20 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.